BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30588573)

  • 1. Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease.
    Gao Y; Wang G; Li Y; Lv C; Wang Z
    J Nephrol; 2019 Apr; 32(2):265-272. PubMed ID: 30588573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
    Ogata H; Fukagawa M; Hirakata H; Kagimura T; Fukushima M; Akizawa T;
    JAMA; 2021 May; 325(19):1946-1954. PubMed ID: 34003226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial.
    Ogata H; Fukagawa M; Hirakata H; Kagimura T; Akizawa T;
    Clin Exp Nephrol; 2022 Dec; 26(12):1223-1232. PubMed ID: 36064876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
    J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and baseline characteristics of the LANDMARK study.
    Ogata H; Fukagawa M; Hirakata H; Kaneda H; Kagimura T; Akizawa T;
    Clin Exp Nephrol; 2017 Jun; 21(3):531-537. PubMed ID: 27405619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.
    Wald R; Rabbat CG; Girard L; Garg AX; Tennankore K; Tyrwhitt J; Smyth A; Rathe-Skafel A; Gao P; Mazzetti A; Bosch J; Yan AT; Parfrey P; Manns BJ; Walsh M
    Clin J Am Soc Nephrol; 2017 Jun; 12(6):965-973. PubMed ID: 28550080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
    Zhao L; Liu A; Xu G
    Ren Fail; 2021 Dec; 43(1):1378-1393. PubMed ID: 34602015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal use of phosphate binders in chronic kidney disease.
    Sonikian M; Papachristou E; Goumenos DS
    Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
    Beaubien-Souligny W; Bezzaoucha S; Pichette V; Lafrance JP; Bell R; Lamarche C; Ouimet D; Vallee M
    Int Urol Nephrol; 2015 Jul; 47(7):1165-71. PubMed ID: 25982583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral activated charcoal suppresses hyperphosphataemia in haemodialysis patients.
    Wang Z; Cui M; Tang L; Li W; Wei Y; Zhu Z; Jia X; Kong X; Xu D
    Nephrology (Carlton); 2012 Sep; 17(7):616-20. PubMed ID: 22697887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
    Hanafusa N
    Clin Calcium; 2015 May; 25(5):711-21. PubMed ID: 25926575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of First-Line Sevelamer and Lanthanum versus Calcium-Based Binders for Hyperphosphatemia of Chronic Kidney Disease.
    Habbous S; Przech S; Martin J; Garg AX; Sarma S
    Value Health; 2018 Mar; 21(3):318-325. PubMed ID: 29566839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.
    Zhai CJ; Yang XW; Sun J; Wang R
    Int Urol Nephrol; 2015 Mar; 47(3):527-35. PubMed ID: 25399356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of phosphate binders in chronic kidney disease.
    Ketteler M; Biggar PH
    Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of metabolic predisposition to cardiovascular complications of chronic kidney disease by effervescent calcium magnesium citrate: a feasibility study.
    Quiñones H; Hamdi T; Sakhaee K; Pasch A; Moe OW; Pak CYC
    J Nephrol; 2019 Feb; 32(1):93-100. PubMed ID: 30465137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats.
    de Castro BBA; do Carmo WB; de Albuquerque Suassuna PG; Carminatti M; Brito JB; Dominguez WV; de Oliveira IB; Jorgetti V; Custodio MR; Sanders-Pinheiro H
    Exp Biol Med (Maywood); 2018 May; 243(9):796-802. PubMed ID: 29763365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of phosphate binders in moderate CKD.
    Block GA; Wheeler DC; Persky MS; Kestenbaum B; Ketteler M; Spiegel DM; Allison MA; Asplin J; Smits G; Hoofnagle AN; Kooienga L; Thadhani R; Mannstadt M; Wolf M; Chertow GM
    J Am Soc Nephrol; 2012 Aug; 23(8):1407-15. PubMed ID: 22822075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
    Hutchison AJ; Laville M;
    Nephrol Dial Transplant; 2008 Nov; 23(11):3677-84. PubMed ID: 18577536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
    Habbous S; Przech S; Acedillo R; Sarma S; Garg AX; Martin J
    Nephrol Dial Transplant; 2017 Jan; 32(1):111-125. PubMed ID: 27651467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.